NEWS
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
Aadi Bioscience (NASDAQ: AADI) has announced the halt of its PRECISION1 trial for nab-sirolimus in solid tumors with TSC1 or TSC2 alterations due to unlikely regulatory approval. The company will now focus on its FYARRO® commercial business for PEComa and conduct a strategic review. To extend cash runway into at least 2H 2026, Aadi will:
Adjust ongoing Phase 2 trials
Reduce R&D headcount by 80%
Pause new enrollment in EEC and NET trials
Continue dosing previously enrolled patients
FYARRO® sales reached $6.2M in Q2. The company will provide a full analysis of the PRECISION1 trial later and has hired an advisory firm to explore options for maximizing shareholder value.
Adjust ongoing Phase 2 trials
Reduce R&D headcount by 80%
Pause new enrollment in EEC and NET trials
Continue dosing previously enrolled patients
FYARRO® sales reached $6.2M in Q2. The company will provide a full analysis of the PRECISION1 trial later and has hired an advisory firm to explore options for maximizing shareholder value.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2317Followers
106Following
24KVisitors
Follow